ProfileGDS5678 / 1449956_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 64% 64% 61% 64% 64% 67% 63% 63% 64% 63% 64% 63% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8430664
GSM967853U87-EV human glioblastoma xenograft - Control 23.8114864
GSM967854U87-EV human glioblastoma xenograft - Control 33.8114764
GSM967855U87-EV human glioblastoma xenograft - Control 43.61561
GSM967856U87-EV human glioblastoma xenograft - Control 53.7939364
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.905164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0822367
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7668663
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.756663
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7962864
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7794763
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.786264
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8089663
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0950567